Ipsen Regulated Information | Investor Relations

Period

Filter by

Reset

Showing: 1 – 05 of 173 Regulated Information

Show

Sort

21 January 2026

21 January 2026

Download Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

07 January 2026

07 January 2026

Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

06 January 2026

06 January 2026

Download Ipsen – Half year statement – 2025 12 31

Ipsen – Half year statement – 2025 12 31

19 December 2025

19 December 2025

Download Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

15 December 2025

15 December 2025

Download Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

1 2 3 4 5 6 7 … 35